The erythromycin-resistance in S. pyogenes does not limit the human polymorphonuclear cell and antimicrobial activity

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 239-242

  Cuffini, Anna Maria ^a   Tullio, V ^a   Banche, G ^a   Allizond, V ^a   Mandras, N ^a   Roana, J ^a   Scalas, D ^a   Carlone, N A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Erythromycin; Erythromycin resistance; Human PMNs; Intracellular killing; Phagocytosis; Streptococcus pyogenes

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISK DIFFUSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INTRACELLULAR KILLING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES;

EID: 62649146053     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200127     Document Type: Article

References (10)

1. Morrissey I, Robbins M, Viljoen L, Brown DF. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. J Antimicrob Chemother 2007; 55:200-8.
2. Banche G, Roana J, Allizond V, et al. In vitro compared activity of telithromycin and azithromycin against Northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. Lett Appl Microbiol 2008; 47:309-14.
3. Voyich JM, Musser JM, DeLeo F.R. Streptococcus pyogenes and human neutrophils: a paradigm for evasion of innate host defense by bacterial pathogens. Microbes Infect 2004; 12:1117-23.
4. Staali L, Bauer S, Mörgelin Björck, Tapper H. Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. Cell Microbiol 2006; 8:690-703.
5. Tullio V, Cuffini AM, Banche G, et al. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic urernic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol 2008; 21:153-60.
6. Giovanetti E, Montanari MP, Mingoia M, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob Agents Chemother 1999; 43:1935-40.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 17th informational supplement. Approved standard M100-S17. Clinical and laboratory Standards Institute, Wayne, Pa 2007.
8. Cuffini AM, Tullio V, Giacchino F, Mandras N, Scalas D, Belardi P, Merlino C, Carlone NA. Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients. Am J Kidney Dis 2001; 37:1253-9.
9. Banche G, Allizond V, Giacchino F, et al. Effect of dialysis membrane biocompatibility on polymorphonuclear granulocyte activity in dialysis patients. Nephrol Dial Transplant 2006; 21:3532-8.
10. Amsden GW. Pneumococcal macrolide resistance-not a myth [reply]. J Antimicrob Chemother 2000; 45:402.